Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib
Shintaro Azuma(Kitasato University Hospital), Koichiro Atsuda(Kitasato University Hospital), Xue Shao(Second Affiliated Hospital of Jilin University), Makoto Chuma(Yokohama City University Medical Center), Kazushi Numata(Yokohama City University Medical Center), Makoto Kako(Shonan Kamakura General Hospital), Takahide Nakazawa(Kitasato University Hospital), Masaaki Kondo(Yokohama City University Medical Center), Wasaburo Koizumi(Kitasato University), Haruki Uojima(National Center for Global Health and Medicine), Shin Maeda(University of Tokyo Hospital), Shogo Iwabuchi(Jikei University School of Medicine), Hisashi Hidaka(Kitasato University)
Cited by 12
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k
KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II.
|Journal of Biological Chemistry|1990|625
N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation.
|Proceedings of the National Academy of Sciences|1981|586